Who are BG00012 (DMF) (Tecfidera®.)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BG00012 (DMF), BG00012 (dimethyl fumarate).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bg00012-dmf-tecfidera.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BG00012 (DMF) (Tecfidera®.) — Competitive Intelligence Brief

BG00012 (DMF) (Tecfidera®.) (BG00012 (DMF) (Tecfidera®.)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fumaric acid ester; Nrf2 activator. Area: Neurology; Immunology.

marketed Fumaric acid ester; Nrf2 activator Nuclear factor erythroid 2-related factor 2 (Nrf2) Neurology; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

BG00012 (DMF) (Tecfidera®.) (BG00012 (DMF) (Tecfidera®.)) — Multiple Sclerosis Center of Northeastern New York. BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and modulate immune responses in the central nervous system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BG00012 (DMF) (Tecfidera®.) TARGET	BG00012 (DMF) (Tecfidera®.)	Multiple Sclerosis Center of Northeastern New York	marketed	Fumaric acid ester; Nrf2 activator	Nuclear factor erythroid 2-related factor 2 (Nrf2)
BG00012 (DMF)	BG00012 (DMF)	Biogen	marketed	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)
BG00012 (dimethyl fumarate)	BG00012 (dimethyl fumarate)	Biogen	phase 3	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fumaric acid ester; Nrf2 activator class)

Multiple Sclerosis Center of Northeastern New York · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BG00012 (DMF) (Tecfidera®.) — Competitive Intelligence Brief. https://druglandscape.com/ci/bg00012-dmf-tecfidera. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab